Cryoport, Inc. (CYRX) - Stock Analysis
Last updated: Jun 21, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Weak Profitability ⢠Higher Valuation CYRX has strong liquidity and manageable leverage, but persistent operating losses and negative free cash flow mean the business is still not self-funding despite a higher valuation.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Cooling momentum ⢠Resistance test Support Level: $14.40â$14.60, with stronger support near $14.00 Resistance Level: $15.50â$15.70, then $16.20â$16.50 Over the last month, CYRX remains in a constructive uptrend with higher lows intact, but momentum has cooled after the $16.50 peak and it must reclaim $15.70 to challenge $16.20â$16.50 while holding $14.00 support.
AI Summary
CYRX has shifted from a âsurvivalâ story to a âprove-itâ story: Q1 growth, narrower losses, and raised guidance support the trend, but the stock's rerating means investors now need clear evidence that revenue gains can translate into positive operating cash flow before the valuation can be justified.
Description
Cryoport, Inc. provides temperature-controlled logistics and related services for life sciences customers across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Its offerings include shipment management software, condition-monitoring and tracking tools, cryogenic transport equipment, and storage and handling services for biological materials. The company serves the biopharma, animal health, and human reproductive medicine markets and was founded in 1999 in Brentwood, Tennessee.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | CYRX | Cryoport, Inc. | Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days. | Closed | +4.4% |